NewLink Genetics Corporation (NLNK) financial statements (2021 and earlier)

Company profile

Business Address 2503 SOUTH LOOP DRIVE
AMES, IA 50010
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9112115913119619061
Cash and cash equivalents9112115913119619061
Receivables11116 161
Prepaid expense   6581
Other undisclosed current assets366258161
Total current assets:9412717516820823064
Noncurrent Assets
Operating lease, right-of-use asset1
Nontrade receivables 00   
Property, plant and equipment24571087
Total noncurrent assets:24571087
TOTAL ASSETS:9713118117521923871
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities119223713124
Accounts payable01923421
Accrued liabilities1081214993
Taxes payable0   1 0
Debt0000100
Deferred rent credit 0
Liability for uncertainty in income taxes1      
Deferred revenue and credits001130
Other undisclosed current liabilities0      
Total current liabilities:129223815254
Noncurrent Liabilities
Long-term debt and lease obligation, including:0000010
Capital lease obligations     0
Operating lease, liability0
Other undisclosed long-term debt and lease obligation 00001 
Liabilities, other than long-term debt 111221
Deferred revenue and credits11221
Deferred rent credit 1
Other undisclosed noncurrent liabilities6666667
Total noncurrent liabilities:6777898
Total liabilities:18162945233412
Stockholders' equity
Stockholders' equity attributable to parent, including:79115152129195203194
Treasury stock, value(1)(1)(1)(1)(1)(0) 
Additional paid in capital414407390296277237194
Accumulated deficit(334)(291)(237)(166)(80)(33) 
Other undisclosed stockholders' equity attributable to parent000    
Other undisclosed stockholders' equity   000(136)
Total stockholders' equity:7911515212919620458
TOTAL LIABILITIES AND EQUITY:9713118117521923871

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net2936691731
Gross profit:1122936691731
Operating expenses(46)(75)(102)(127)(102)(55)(32)
Other undisclosed operating income  0    
Operating income (loss):(45)(62)(73)(91)(34)118(31)
Nonoperating income (expense)2200(0)00
Investment income, nonoperating221  00
Other nonoperating income (expense)(0)(0)(0)0(0)00
Interest and debt expense(0)(0)(0)0(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   (0)0(0)0
Income (loss) from continuing operations before equity method investments, income taxes:(43)(61)(73)(91)(34)118(31)
Other undisclosed income from continuing operations before income taxes000    
Income (loss) from continuing operations before income taxes:(43)(61)(73)(91)(34)118(31)
Income tax expense (benefit)(0)715(7)(15)(0)
Net income (loss) available to common stockholders, diluted:(43)(54)(72)(85)(40)103(31)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(43)(54)(72)(85)(40)103(31)
Comprehensive income (loss), net of tax, attributable to parent:(43)(54)(72)(85)(40)103(31)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: